Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

Christos N. Papandreou, Danai D. Daliani, Darrell Nix, Hong Yang, Timothy Madden, Xuemei Wang, Christine S. Pien, Randall E. Millikan, Shi Ming Tu, Lance Pagliaro, Jeri Kim, Julian Adams, Peter Elliott, Dixie Esseltine, Alexandria Petrusich, Pauline Dieringer, Cherie Perez, Christopher J. Logothetis

Research output: Contribution to journalArticle

403 Citations (Scopus)

Abstract

Purpose: To determine the dose-limiting toxicity and maximum-tolerated dose of the proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5 weeks; to determine the bortezomib pharmacokinetics and pharmacodynamics using plasma levels and an assay for 20S proteasome inhibition (PI) in whole blood; to correlate toxicity with bortezomib dose and degree of 20S PI; and to conduct a preliminary determination of the antitumor activity of bortezomib in patients with androgen independent prostate cancer (AIPCa). Patients and Methods: Fifty-three patients (48 with AIPCa) received 128 cycles of bortezomib in doses ranging from 0.13 to 2.0 mg/m2/dose, utilizing a careful escalation scheme with a continuous reassessment method. Pharmacokinetic and pharmacodynamic studies were performed in 24 patients (at 1.45 to 2.0 mg/m 2). Results: A dose-related 20S PI was seen, with dose-limiting toxicity at 2.0 mg/m2 (diarrhea, hypotension) occurring at an average 1-hour post-dose of ≥ 75% 20S PI. Other side effects were fatigue, hypertension, constipation, nausea, and vomiting. No relationship was seen between body-surface area and bortezomib clearance over the narrow dose range tested. There was evidence of biologic activity (decline in serum prostate-specific antigen and interleukin-6 levels) at & 50% 20S PI. Two patients with AIPCa had prostate-specific antigen response and two patients had partial response in lymph nodes. Conclusion: The maximum-tolerated dose and recommended phase II dose of bortezomib in this schedule is 1.6 mg/m 2. Biologic activity (inhibition of nuclear factor-kappa B-related markers) and antitumor activity is seen in AIPCa at tolerated doses of bortezomib. This agent should be further explored with chemotherapy agents in advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)2108-2121
Number of pages14
JournalJournal of Clinical Oncology
Volume22
Issue number11
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Androgens
Prostatic Neoplasms
Proteasome Endopeptidase Complex
Neoplasms
Maximum Tolerated Dose
Prostate-Specific Antigen
Pharmacokinetics
Proteasome Inhibitors
benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal
Bortezomib
NF-kappa B
Body Surface Area
Constipation
Hypotension
Nausea
Vomiting
Fatigue
Diarrhea
Interleukin-6
Appointments and Schedules

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. / Papandreou, Christos N.; Daliani, Danai D.; Nix, Darrell; Yang, Hong; Madden, Timothy; Wang, Xuemei; Pien, Christine S.; Millikan, Randall E.; Tu, Shi Ming; Pagliaro, Lance; Kim, Jeri; Adams, Julian; Elliott, Peter; Esseltine, Dixie; Petrusich, Alexandria; Dieringer, Pauline; Perez, Cherie; Logothetis, Christopher J.

In: Journal of Clinical Oncology, Vol. 22, No. 11, 2004, p. 2108-2121.

Research output: Contribution to journalArticle

Papandreou, CN, Daliani, DD, Nix, D, Yang, H, Madden, T, Wang, X, Pien, CS, Millikan, RE, Tu, SM, Pagliaro, L, Kim, J, Adams, J, Elliott, P, Esseltine, D, Petrusich, A, Dieringer, P, Perez, C & Logothetis, CJ 2004, 'Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer', Journal of Clinical Oncology, vol. 22, no. 11, pp. 2108-2121. https://doi.org/10.1200/JCO.2004.02.106
Papandreou, Christos N. ; Daliani, Danai D. ; Nix, Darrell ; Yang, Hong ; Madden, Timothy ; Wang, Xuemei ; Pien, Christine S. ; Millikan, Randall E. ; Tu, Shi Ming ; Pagliaro, Lance ; Kim, Jeri ; Adams, Julian ; Elliott, Peter ; Esseltine, Dixie ; Petrusich, Alexandria ; Dieringer, Pauline ; Perez, Cherie ; Logothetis, Christopher J. / Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 11. pp. 2108-2121.
@article{b8465fca637e4f52b307f04514a3466e,
title = "Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer",
abstract = "Purpose: To determine the dose-limiting toxicity and maximum-tolerated dose of the proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5 weeks; to determine the bortezomib pharmacokinetics and pharmacodynamics using plasma levels and an assay for 20S proteasome inhibition (PI) in whole blood; to correlate toxicity with bortezomib dose and degree of 20S PI; and to conduct a preliminary determination of the antitumor activity of bortezomib in patients with androgen independent prostate cancer (AIPCa). Patients and Methods: Fifty-three patients (48 with AIPCa) received 128 cycles of bortezomib in doses ranging from 0.13 to 2.0 mg/m2/dose, utilizing a careful escalation scheme with a continuous reassessment method. Pharmacokinetic and pharmacodynamic studies were performed in 24 patients (at 1.45 to 2.0 mg/m 2). Results: A dose-related 20S PI was seen, with dose-limiting toxicity at 2.0 mg/m2 (diarrhea, hypotension) occurring at an average 1-hour post-dose of ≥ 75{\%} 20S PI. Other side effects were fatigue, hypertension, constipation, nausea, and vomiting. No relationship was seen between body-surface area and bortezomib clearance over the narrow dose range tested. There was evidence of biologic activity (decline in serum prostate-specific antigen and interleukin-6 levels) at & 50{\%} 20S PI. Two patients with AIPCa had prostate-specific antigen response and two patients had partial response in lymph nodes. Conclusion: The maximum-tolerated dose and recommended phase II dose of bortezomib in this schedule is 1.6 mg/m 2. Biologic activity (inhibition of nuclear factor-kappa B-related markers) and antitumor activity is seen in AIPCa at tolerated doses of bortezomib. This agent should be further explored with chemotherapy agents in advanced prostate cancer.",
author = "Papandreou, {Christos N.} and Daliani, {Danai D.} and Darrell Nix and Hong Yang and Timothy Madden and Xuemei Wang and Pien, {Christine S.} and Millikan, {Randall E.} and Tu, {Shi Ming} and Lance Pagliaro and Jeri Kim and Julian Adams and Peter Elliott and Dixie Esseltine and Alexandria Petrusich and Pauline Dieringer and Cherie Perez and Logothetis, {Christopher J.}",
year = "2004",
doi = "10.1200/JCO.2004.02.106",
language = "English (US)",
volume = "22",
pages = "2108--2121",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

AU - Papandreou, Christos N.

AU - Daliani, Danai D.

AU - Nix, Darrell

AU - Yang, Hong

AU - Madden, Timothy

AU - Wang, Xuemei

AU - Pien, Christine S.

AU - Millikan, Randall E.

AU - Tu, Shi Ming

AU - Pagliaro, Lance

AU - Kim, Jeri

AU - Adams, Julian

AU - Elliott, Peter

AU - Esseltine, Dixie

AU - Petrusich, Alexandria

AU - Dieringer, Pauline

AU - Perez, Cherie

AU - Logothetis, Christopher J.

PY - 2004

Y1 - 2004

N2 - Purpose: To determine the dose-limiting toxicity and maximum-tolerated dose of the proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5 weeks; to determine the bortezomib pharmacokinetics and pharmacodynamics using plasma levels and an assay for 20S proteasome inhibition (PI) in whole blood; to correlate toxicity with bortezomib dose and degree of 20S PI; and to conduct a preliminary determination of the antitumor activity of bortezomib in patients with androgen independent prostate cancer (AIPCa). Patients and Methods: Fifty-three patients (48 with AIPCa) received 128 cycles of bortezomib in doses ranging from 0.13 to 2.0 mg/m2/dose, utilizing a careful escalation scheme with a continuous reassessment method. Pharmacokinetic and pharmacodynamic studies were performed in 24 patients (at 1.45 to 2.0 mg/m 2). Results: A dose-related 20S PI was seen, with dose-limiting toxicity at 2.0 mg/m2 (diarrhea, hypotension) occurring at an average 1-hour post-dose of ≥ 75% 20S PI. Other side effects were fatigue, hypertension, constipation, nausea, and vomiting. No relationship was seen between body-surface area and bortezomib clearance over the narrow dose range tested. There was evidence of biologic activity (decline in serum prostate-specific antigen and interleukin-6 levels) at & 50% 20S PI. Two patients with AIPCa had prostate-specific antigen response and two patients had partial response in lymph nodes. Conclusion: The maximum-tolerated dose and recommended phase II dose of bortezomib in this schedule is 1.6 mg/m 2. Biologic activity (inhibition of nuclear factor-kappa B-related markers) and antitumor activity is seen in AIPCa at tolerated doses of bortezomib. This agent should be further explored with chemotherapy agents in advanced prostate cancer.

AB - Purpose: To determine the dose-limiting toxicity and maximum-tolerated dose of the proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5 weeks; to determine the bortezomib pharmacokinetics and pharmacodynamics using plasma levels and an assay for 20S proteasome inhibition (PI) in whole blood; to correlate toxicity with bortezomib dose and degree of 20S PI; and to conduct a preliminary determination of the antitumor activity of bortezomib in patients with androgen independent prostate cancer (AIPCa). Patients and Methods: Fifty-three patients (48 with AIPCa) received 128 cycles of bortezomib in doses ranging from 0.13 to 2.0 mg/m2/dose, utilizing a careful escalation scheme with a continuous reassessment method. Pharmacokinetic and pharmacodynamic studies were performed in 24 patients (at 1.45 to 2.0 mg/m 2). Results: A dose-related 20S PI was seen, with dose-limiting toxicity at 2.0 mg/m2 (diarrhea, hypotension) occurring at an average 1-hour post-dose of ≥ 75% 20S PI. Other side effects were fatigue, hypertension, constipation, nausea, and vomiting. No relationship was seen between body-surface area and bortezomib clearance over the narrow dose range tested. There was evidence of biologic activity (decline in serum prostate-specific antigen and interleukin-6 levels) at & 50% 20S PI. Two patients with AIPCa had prostate-specific antigen response and two patients had partial response in lymph nodes. Conclusion: The maximum-tolerated dose and recommended phase II dose of bortezomib in this schedule is 1.6 mg/m 2. Biologic activity (inhibition of nuclear factor-kappa B-related markers) and antitumor activity is seen in AIPCa at tolerated doses of bortezomib. This agent should be further explored with chemotherapy agents in advanced prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=2942692143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942692143&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.02.106

DO - 10.1200/JCO.2004.02.106

M3 - Article

C2 - 15169797

AN - SCOPUS:2942692143

VL - 22

SP - 2108

EP - 2121

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -